SCHEMBL19616936

SCHEMBL19616936

COCCN1CCC[C@H]1COCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV6 Q9H1D0 1/20 0.55
HTR1D P28221 2/20 0.48
HTR1B P28222 2/20 0.48
DRD2 P14416 2/20 0.45
HTR2A P28223 2/20 0.45
HTR2C P28335 2/20 0.45
HRH3 Q9Y5N1 3/20 0.44
ADRA1A P35348 1/20 0.44
HRH1 P35367 1/20 0.44
ADRA1B P35368 1/20 0.44
KCNH2 Q12809 1/20 0.44
VEGFA P15692 1/20 0.43
EGLN1 Q9GZT9 1/20 0.43
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
CTSK P43235 1/20 0.43
CHRNB2 P17787 1/20 0.43
CHRNA5 P30532 1/20 0.43
CHRNA7 P36544 1/20 0.43
CHRNA4 P43681 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19617897 1.00 TRPV6 (0.55) TRPV6HTR1DHTR1BDRD2HTR2A
SCHEMBL21908568 0.83 TRPV6 (0.50) TRPV6HTR1DHTR1BHRH3CTSL
SCHEMBL19947782 0.83 TRPV6 (0.50) TRPV6HTR1DHTR1BHRH3CTSL
SCHEMBL19948638 0.83 TRPV6 (0.50) TRPV6HTR1DHTR1BHRH3CTSL
SCHEMBL22110284 0.83 CHRNB2 (0.57) KCNH2CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL14502963 0.83 CHRNB2 (0.57) KCNH2CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL6166949 0.83 TRPV6 (0.51) TRPV6HTR1DHTR1BHRH3CTSL
SCHEMBL22994657 0.78 CTSL (0.40) CTSLCTSBCTSK
SCHEMBL19637285 0.78 CTSL (0.40) CTSLCTSBCTSK
SCHEMBL23546142 0.78 LTA4H (0.46) TRPV6HTR1DHTR1BHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 CN disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 US disclosed
CN-109843856-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2023-05-02 CN disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 EP disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 EP disclosed
US-11267812-B2 KRAS G12C inhibitors Mirati Therapeutics, Inc. (US) 2022-03-08 US disclosed
US-11267812-B2 KRAS G12C inhibitors Mirati Therapeutics, Inc. (US) 2022-03-08 US disclosed
CN-109843856-A KRAS G12C inhibitor 米拉蒂治疗股份有限公司 2019-06-04 CN disclosed
US-20190144444-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-05-16 US disclosed
US-20190144444-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-05-16 US disclosed
EP-3458445-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2019-03-27 EP disclosed
US-10125134-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2018-11-13 US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 US disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 WO disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144444-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TRPV6 4247/4885HTR1D 4689/4885HTR1B 4451/4885
US-11267812-B2 KRAS G12C inhibitors KRAS, NRAS, HRAS TRPV6 4247/4885HTR1D 4689/4885HTR1B 4451/4885
US-10125134-B2 KRas G12C inhibitors KRAS, NRAS, HRAS TRPV6 4247/4885HTR1D 4689/4885HTR1B 4451/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TRPV6 4247/4885HTR1D 4689/4885HTR1B 4451/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TRPV6 4247/4885HTR1D 4689/4885HTR1B 4451/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TRPV6 4247/4885HTR1D 4689/4885HTR1B 4451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.